Spamdex - Spam Archive

Report spam

Send in your spam and get the offenders listed

Create a rule in outlook or simply forward the spam you receive to questions@spamdex.co.uk

Also in service.govdelivery.com

U.S. Food & Drug Administration (FDA) Clinical Pharmacology Corner FDA Approves IRESSA (gefitinib)

Clinical Pharmacology Corner Banner

FDA Approves IRESSA® (gefitinib) for Treating Locally Advanced or Metastatic Non-Small Cell Lung Cancer Expressing Epidermal Growth Factor Receptor (EGFR) Exon 19 Deletion or Exon 21 (L858R) Substitution Mutations

On July 13, 2015, the United States Food and Drug Administration (FDA) approved IRESSA (gefitinib) tablets, an epidermal grow factor receptor (EGFR) tyrosine kinase inhibitor, for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. The recommended dose of IRESSA tablets is 250 mg orally once daily (QD) taken with or without food. The following are key clinical pharmacology related highlights from the regulatory review of this application:

General Pharmacokinetics and Pharmacodynamics of Gefitinib

  • Absolute bioavailability (tablets): 59% (Tmax of 3-5 hours) in cancer patients.
  • Plasma protein binding: 91%.
  • Terminal half-life (mean): 41 hours.
  • Metabolism: Extensive. Predominately by CYP3A and CYP2D6.
  • Excretion: Less than 4% of parent and metabolites are excreted via the kidney.
  • Exposure-safety: Dose reduction due to toxicity was relatively low in the Phase 2 studies in NSCLC patients (~10%) when the recommended dose was doubled. An exploratory exposure response analysis showed an increase in the incidence of interstitial lung disease (ILD) with a greater than 2 fold increase in the gefitinib exposure.

Drug Interaction Potential

  • International Normalized Ratio (INR) elevations and/or hemorrhage have been reported in some patients taking warfarin while on IRESSA therapy.
  • A ranitidine induced increase in gastric pH to 5 or greater reduced the gefitinib exposure (AUC) by 47% and Cmax by 71% in a clinical study. Avoid concomitant use of proton pump inhibitors (PPI), if possible.  If treatment with a PPI is required, IRESSA should be taken 12 hours after the last dose or 12 hours before the next dose of the PPI.  IRESSA can be taken 6 hours after or 6 hours before an H2-receptor antagonist or an antacid.
  • Coadministration with a strong CYP3A4 inducer (i.e., rifampicin) decreased gefitinib exposure by 83% in a clinical study. Increase IRESSA dosage to 500 mg daily when it is co-administered with a strong CYP3A4 inducer.
  • Coadministration with a strong CYP3A4 inhibitor (itraconazole) increased gefitinib exposure by 80% in a clinical study. However, no dose adjustment is recommended with co-administration of a strong CYP3A4 inhibitor based on the observed less than 1% dose reduction rate with the 250 mg daily dose regimen and 10% dose reduction rate when the recommended dosage was doubled in clinical studies.
  • Gefitinib is a substrate of P-glycoprotein in vitro. Transporter saturation was observed at higher concentrations.  The clinical implications of these findings are not known.

Use in Specific Populations

  • Exposure to gefitinib was approximately 1.4-, 3.6-, and 2.7-fold higher in subjects with mild, moderate, and severe cirrhotic hepatic impairment, respectively, compared to subjects with normal hepatic function in a clinical study.  Therefore, cirrhotic patients should be monitored frequently for signs of increased toxicities. In a separate study in cancer patients with hepatic impairment secondary to liver metastases, gefitinib exposures were similar in patients with moderate and severe metastatic hepatic impairment compared to patients with normal hepatic function. Therefore, a dose adjustment is not recommended patients with hepatic impairment secondary to liver metastases
  • Healthy CYP2D6 poor metabolizers had 2.1-fold higher gefitinib exposure compared to extensive metabolizers. However, a dose adjustment is not recommended due to the low rate of dose adjustment at this exposure in clinical studies. These patients should be monitored frequently for signs of increased toxicities.
  • No clinical studies were conducted with IRESSA in patients with severe renal impairment.

Safety and Efficacy

The efficacy and safety of IRESSA was demonstrated in a multicenter, single-arm, open-label clinical trial. The primary endpoint of objective response rate was 50% [95% confidence interval (CI): 40, 60]. The median duration of response was 6 months (95% CI: 5.6, 11.1 months). These results were supported by another randomized trial which reported that a retrospective analysis of the subgroup of 186 EGFR mutation-positive patients suggested an improvement in progression free survival with IRESSA (n=88) compared to carboplatin/paclitaxel (n=98).

The most common adverse events (AEs) were rash, diarrhea, dry skin, nausea, vomiting, cough, and asthenia. Interstitial lung disease, a known AE associated with gefitinib use that is more common in Asian patients, was reported in 1 (1%) Caucasian patient and in 16 (2.6%) Asian patients.



Full prescribing information is available at http://go.usa.gov/3fHuv.
The Office of Clinical Pharmacology (OCP) regulatory reviews for new drugs or biologics are often available for viewing shortly following approval at the Agency's Drugs@FDA website (http://go.usa.gov/3fHuM).

We always welcome your thoughts regarding the format, content, and utility of information you receive via this Burst email initiative. Comments may be sent via email to ocp@fda.hhs.gov.

This Burst was prepared by the Clinical Pharmacology Review Team including Robert Schuck, Clinical Pharmacologist, Genomics and Targeted Therapy Group, and Hong Zhao, Team Leader, Division of Clinical Pharmacology V, Office of Clinical Pharmacology, Office of Translational Sciences, CDER, FDA.

FDA/Center for Drug Evaluation and Research (CDER)
Office of Translational Sciences
Office of Clinical Pharmacology
Email: ocp@fda.hhs.gov


This email was sent to using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 Powered by GovDelivery

---------------------------

All titles, content, publisher names, trademarks, artwork, and associated imagery are trademarks and/or copyright material of their respective owners. All rights reserved. The Spam Archive website contains material for general information purposes only. It has been written for the purpose of providing information and historical reference containing in the main instances of business or commercial spam.

Many of the messages in Spamdex's archive contain forged headers in one form or another. The fact that an email claims to have come from one email address or another does not mean it actually originated at that address! Please use spamdex responsibly.


Yes YOU! Get INVOLVED - Send in your spam and report offenders

Create a rule in outlook or simply forward the junk email you receive to questions@spamdex.co.uk | See contributors

Google + Spam 2010- 2017 Spamdex - The Spam Archive for the internet. unsolicited electric messages (spam) archived for posterity. Link to us and help promote Spamdex as a means of forcing Spammers to re-think the amount of spam they send us.

The Spam Archive - Chronicling spam emails into readable web records index for all time

Please contact us with any comments or questions at questions@spamdex.co.uk. Spam Archive is a non-profit library of thousands of spam email messages sent to a single email address. A number of far-sighted people have been saving all their spam and have put it online. This is a valuable resource for anyone writing Bayesian filters. The Spam Archive is building a digital library of Internet spam. Your use of the Archive is subject to the Archive's Terms of Use. All emails viewed are copyright of the respected companies or corporations. Thanks to Benedict Sykes for assisting with tech problems and Google Indexing, ta Ben.

Our inspiration is the "Internet Archive" USA. "Libraries exist to preserve society's cultural artefacts and to provide access to them. If libraries are to continue to foster education and scholarship in this era of digital technology, it's essential for them to extend those functions into the digital world." This is our library of unsolicited emails from around the world. See https://archive.org. Spamdex is in no way associated though. Supporters and members of http://spam.abuse.net Helping rid the internet of spam, one email at a time. Working with Inernet Aware to improve user knowlegde on keeping safe online. Many thanks to all our supporters including Vanilla Circus for providing SEO advice and other content syndication help | Link to us | Terms | Privacy | Cookies | Complaints | Copyright | Spam emails / ICO | Spam images | Sitemap | All hosting and cloud migration by Cloudworks.

Important: Users take note, this is Spamdex - The Spam Archive for the internet. Some of the pages indexed could contain offensive language or contain fraudulent offers. If an offer looks too good to be true it probably is! Please tread, carefully, all of the links should be fine. Clicking I agree means you agree to our terms and conditions. We cannot be held responsible etc etc.

The Spam Archive - Chronicling spam emails into readable web records

The Glass House | London | SW19 8AE |
Spamdex is a digital archive of unsolicited electronic mail 4.9 out of 5 based on reviews
Spamdex - The Spam Archive Located in London, SW19 8AE. Phone: 08000 0514541.